Illumina to release new version of its flagship cancer research assay, TruSight Oncology 500 v2: San Diego Thursday, November 21, 2024, 16:00 Hrs [IST] Illumina, Inc., a global le ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer ...

Shares of Illumina (NASDAQ:ILMN) fell 6% post-market Monday after the company lowered its fiscal 2024 revenue guidance. The ...

Report on how AI is driving market transformation - The global DNA sequencing market size is estimated to grow by USD 17.34 ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will ...

Illumina, a United States-headquartered company specializing in DNA sequencing and array-based technologies, is showcasing ...

The Institute of Genomics and Global Health, formerly known as the African Centre of Excellence for Genomics of Infectious ...

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its ...